OraSure Technologies (OSUR) : The consensus on OraSure Technologies (OSUR) based on 3 analyst recommendation on the company stock is 1.67, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 2 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
For the current week, the company shares have a recommendation consensus of Buy. Also, Brokerage firm Stephens & Co. upgrades its rating on OraSure Technologies (NASDAQ:OSUR). The shares have been rated Overweight. Previously, the analysts had a Equal-weight rating on the shares. The rating by the firm was issued on August 29, 2016.
OraSure Technologies (NASDAQ:OSUR): The stock opened at $8.6 and touched an intraday high of $8.81 on Wednesday. During the day, the stock corrected to an intraday low of $8.6, however, the bulls stepped in and pushed the price higher to close in the green at $8.77 with a gain of 1.50% for the day. The total traded volume for the day was 658,392. The stock had closed at $8.64 in the previous trading session.
OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices and other diagnostic products designed to detect or diagnose critical medical conditions. These products include OraQuick In-Home HIV Test, OraQuick ADVANCE, OraSure HIV-1 oral specimen collection device, OraQuick HCV rapid antibody test, Intercept oral fluid drug testing system, OraSure QuickFlu Rapid Flu A&B Test and Q.E.D. Saliva Alcohol test. The Company also manufactures and sells a range of cryosurgical products. Through its wholly owned subsidiary, DNA Genotek Inc., the Company provides oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications.